July 9, 2005
For Immediate Release
The Atherosclerosis Treatment Market is an Evolving Battleground, According to July 2005 Issue of MedMarkets from MedMarket Diligence, LLC
FOOTHILL RANCH, CA — The atherosclerosis market is large, complex, and diverse. It will continue to expand rapidly in many directions over the next 5-10 years, with the explosive rise in global atherosclerosis as the primary market driver.
In a market that has evolved from cardiothoracic surgery to interventional cardiology, and the progressive and competitive evolution of both, the treatment of coronary heart disease, and atherosclerosis in general, is characterized by a battle over caseload, with the current balance seemingly defined by the relative benefits of clinical efficacy (patency, low restenosis) and less invasiveness. While the surgical and device arena is almost evenly matched in this respect at the moment, the development of atherosclerosis-reversing drugs, tissue/cell therapeutics and others may signal (in 10+ years, perhaps) the demise of surgical/interventional approaches for treatment of coronary artery disease.
The July 2005 issue of MedMarkets examines the current market balance, details the outlook for surgical/interventional device development and the future market for these and emerging products in the broader market for atherosclerosis treatment.
MedMarkets is published 12 times annually by MedMarket Diligence. Coverage encompasses medical device, biotech, biomaterials and the range of technologies encompassing device market developments and analysis of Interventional Cardiology, Cardiovascular Surgery, Orthopedics/Musculoskeletal, Abdominal & Thoracic Surgery, Gynecology, Oncology, Neurology & Neurosurgery and other clinical sectors. Past coverage may be reviewed at www.mediligence.com/archive2005.html.
MedMarket Diligence provides tactical decision-making solutions on medical
technology to the medical products and investment industries. The company
MedMarkets newsletter, a monthly analysis of the market implications of new
medical technologies, and dedicated reports on technology markets. For
additional details, contact Patrick Driscoll at
email or call
949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.